# 2022-topic-02-team-03: lung adenocarcinoma (LUAD)

Paul Brunner, Marie Kleinert, Felipe Stünkel, Chloé Weiler

### Weekly progress tracking
https://docs.google.com/presentation/d/1kwlgwZ56-xShOw0AJJ2YgdOsa-FFsNZBCRnz7Wb3CKk/edit?usp=sharing

### useful papers
Fast gene set enrichment analysis
Gennady Korotkevich, Vladimir Sukhov, Nikolay Budin, Boris Shpak, Maxim N. Artyomov, Alexey Sergushichev
doi: https://doi.org/10.1101/060012

Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation,
and pharmacological inhibition
DOI: 10.1016/j.phrs.2012.11.007

Therapeutic Potential of Glutamine Pathway in Lung Cancer
Enyu Tang et. all 
DOI: 10.1016/j.phrs.2012.11.007

The nonsmokers' and smokers' pathways in lung adenocarcinoma: Histological progression and molecular bases
https://pubmed.ncbi.nlm.nih.gov/34143937/
DOI: 10.1111/cas.15031

Molecular Alterations in Lung Adenocarcinoma With Ground-Glass Nodules: A Systematic Review and Meta-Analysis
https://www.frontiersin.org/articles/10.3389/fonc.2021.724692/full
https://doi.org/10.3389/fonc.2021.724692

Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance
https://pubmed.ncbi.nlm.nih.gov/35203491/
DOI: 10.3390/biomedicines10020277
